Table 2.

Background characteristics and study data.

Study	n	Country	Follow-up, months	Drop out, %	Age, mean ± s.d.	Male, %	Macroprolactinoma, %	Treatmenta	Overweight or obese at baseline, %	Baseline prolactin, mU/L mean ± s.d.	Baseline BMI, mean ± s.d.
Schwetz 2017 (25)	53	Austria	9	0	39 ± 17	58	59	CAB	–	7607 ± 4414	27.9 ± 5.9
Iglesias 2016 (32)	27	Spain	57	0	39 ± 13	100	74	CAB	–	43693 ± 27401	31.3 ± 5.1
Auriemma 2015 (26)	32	Italy	24	0	42 ± 5	100	78	CAB	97	42996 ± 93443	31.7 ± 3.9
Auriemma 2014 (5)	61	Italy	60	0	34 ± 10	21	33	CAB	64	16733 ± 5073	27.6 ± 5.3
Barbosa 2014 (33)	21	Brazil	6	40	–	–	23	CAB, BRC	69	9080 ± 7034	29.3 ± 15.4
Ciresi 2013 (4)	43	Italy	12	0	34 ± 11	19	–	CAB	–	3715 ± 5718	25.57 ± 5.18
Inancli 2013 (29)	21	Turkey	6	0	30 ± 10	0	14	CAB	19b	3201 ± 1230	27.1 ± 5.9
Berinder 2011 (6)	14	Sweden	6	7	40 ± 14	43	43	CAB, BRC	21b	M:26809(2617–204,255) /F: 1511(1043–2787)	25.8 ± 7.8
Silva 2011 (8)	22	Brazil	6	37	42 ± 35	23	18	CAB, BRC	62	5720 ± 3621	29.2 ± 15.3
Serri 2006 (7)	15	Canada	3	–	39 ± 13	47	13	CAB	47b	20,160 ± 18,780	29 ± 6
Doknic 2002 (30)	23	Serbia	6	0	37 ± 3	52	65	BRC	39c	42,682 ± 37,429	27.5 ± 3.4
Medic 2015 (31)	20	Serbia	4	0	30 ± 7	0	30	CAB, BRC	–	2919 ± 1102	24 ± 6.4
Pala 2015 (27)	19	India	6	32	27 ± 6	5	21	CAB	37	2514 ± 2232	24.2 ± 4.0
Yavuz 2003 (28)	16	Turkey	6	0	31 ± 10	0	–	BRC	–	3318 ± 1637	26.3 ± 5.3

^aCabergoline (CAB); Bromocriptine (BRC)

^bBMI > 30.

^cBMI > 27.

F, female; M, male.